Polyclonal antithymocyte globulin

This page covers all Polyclonal antithymocyte globulin drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR), T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers).

Targets

Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) · T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers)

Marketed (1)

• anti thymoglobulin · Peking University People's Hospital · Immunology
  Anti-thymoglobulin is a polyclonal antibody that depletes T lymphocytes by binding to antigens on T cells and triggering their destruction.

Phase 3 pipeline (1)

• Individual Antithymocyte globulin · Chinese PLA General Hospital · Immunology
  Antithymocyte globulin (ATG) is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells, thereby suppressing cell-mediated immune responses.